The proposal to switch levonorgestrel emergency contraception(sold under the brand name Plan B) to over-the-counter statusin the United States is in limbo. In May, the Food and DrugAdministration (FDA) rejected the application of Barr Pharmaceuticalsfor nonprescription sales of Plan B. Dr. Steven Galson, theacting director of the FDA's Center for Drug Evaluation andResearch, wrote that the company had "not provided adequatedata to support a conclusion that Plan B can be used safelyby young adolescent women for emergency contraception withoutthe professional supervision of a practitioner licensed by lawto administer the drug." . . . [Full Text of this Article]
Burstein, P. D., Fernandez, J. V., Grant, E. C., Greene, M. F., Drazen, J. M., Wood, A. J.J.
(2005). A Sad Day for Science at the FDA. NEJM
353: 2619-2621
[Full Text]
Schorn, M. N.
(2005). Emergency Contraception for Sexual Assault Victims: An Advocacy Coalition Framework. Policy Politics Nursing Practice
6: 343-353
[Abstract]
Fincham, J. E, Harris, C. E, Fassett, W. E, Richards, W.
(2005). Over-the-Counter Availability of Plan B Emergency Contraception: Further Discussion and Commentary. The Annals of Pharmacotherapy
39: 346-351
[Abstract][Full Text]
Gelijns, A. C., Brown, L. D., Magnell, C., Ronchi, E., Moskowitz, A. J.
(2005). Evidence, Politics, And Technological Change. Health Aff (Millwood)
24: 29-40
[Abstract][Full Text]
Schwarz, E. B.
(2004). Plan B -- The FDA and Emergency Contraception. NEJM
351: 1031-1032
[Full Text]
Fenichel, R. R
(2004). Which drugs should be available over the counter?. BMJ
329: 182-183
[Full Text]